Document is current
Any future updates will be listed below
-
Authors
Ohashi, Takuma https://orcid.org/0000-0002-4354-2032
Aoki, Jun
Ando, Taiki https://orcid.org/0000-0002-2127-0873
Ishiyama, Yasufumi
Ishii, Yoshimi
Miyashita, Kazuho
Nakajima, Yuki
Tachibana, Takayoshi https://orcid.org/0000-0002-7780-4459
Hagihara, Maki
Matsumoto, Kenji
Tanaka, Masatsugu
Kanamori, Heiwa
Fujisawa, Shin
Nakajima, Hideaki https://orcid.org/0000-0002-8967-4954
,
-
Funding
Funding for this research was provided by:
Otsuka America Pharmaceutical
NOVARTIS Foundation (Japan) for the Promotion of Science (NOVARTIS Foundation
Pfizer Inc. | Pfizer Japan
Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada
Daiichi Sankyo Company
Astellas Pharma
Takeda Pharmaceutical Company
Otsuka Pharmaceutical
- License Information
-
More Information
Article History
Received: 12 October 2021
Revised: 28 March 2022
Accepted: 5 April 2022
First Online: 3 May 2022
Competing interests
: TT received personal fees from Otsuka, Novartis, Pfizer, BMS, Daiichi Sankyo, and Astellas, outside the submitted study. SF received research funding from Takeda Pharmaceutical and Otsuka Pharmaceutical. HN received research funding from Daiichi-Sankyo, Chugai Pharmaceuticals, Astellas, Asahikasei pharma, Takeda pharmaceuticals, Pfizer and Eizai, honoraria from Novartis and Daiichi Sankyo.
: This study was performed in accordance with the Declaration of Helsinki and the Ethics Guidelines for Clinical Research published by the Ministry of Health, Labor, and Welfare of Japan. This retrospective study was approved by Ethical Committee for Medical and Biological Research Involving Human Subjects of Yokohama City University Medical Center (B180800006). Approval for the protocol and written informed consent forms were obtained from the ethics committees at each institution. The written decision can be presented upon request.
